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doi:10.1016/j.numecd.2010.12.010Abstract Background and aims: To compare the effects of n-3 long chain polyunsaturated
fatty acids (n-3 LCPUFA), with those of fenofibrate, on markers of inflammation and vascular
function, and on the serum lipoprotein profile in overweight and obese subjects.
Methods and results: Twenty overweight and obese subjects participated in a randomized,
double-blind, placebo-controlled intervention trial and received 3.7 g/d n-3 fatty acids
(providing 1.7 g/d EPA and 1.2 g/d DHA), 200 mg fenofibrate or placebo treatment for 6 weeks
separated by a 2 weeks wash-out period. Fish oil and fenofibrate treatment reduced triglyc-
eride (0.61  0.81 mmol/L, P < 0.001, and 0.34  0.85 mmol/L, P Z 0.048, respectively)
and increased HDL cholesterol concentrations (0.13  0.21 mmol/L, P Z 0.013, and
0.10  0.18 mmol/L, P Z 0.076), as reflected by a decrease of large very VLDL particles
and increases of large HDL particles and medium size HDL particles. Fish oil increased serum
LDL cholesterol concentrations (0.34  0.59 mmol/L, PZ 0.013). Fenofibrate reduced concen-
trations of soluble endothelial selectin (sE-selectin) (4.1  7.5 ng/mL, P Z 0.032), but
increased those of macrophage chemoattractant protein 1 (MCP1) (28  55 ng/mL,
P Z 0.034). Fish oil had no effects on these markers.
Conclusion: Although n-3 LCPUFA and fenofibrate can both activate PPARa, they have differ-
ential effects on cardiovascular risk markers. In overweight and obese subjects fenofibrate
(200 mg/d) or n-3 LCPUFA (3.7 g/d) treatment for 6 weeks did not improve markers for low-ool for Nutrition, Toxicology and Metabolism, Department of Human Biology, Maastricht University
D Maastricht, The Netherlands. Tel.: þ31 6 51341828.
ichtuniversity.nl (M.C.E. Bragt), r.mensink@maastrichtuniversity.nl (R.P. Mensink).
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Drugs of the fibrate class, such as fenofibrate, are potent
activators of Peroxisome Proliferator Activated Receptor
a (PPARa) [1]. These lipid-lowering drugs effectively reduce
triglyceride, moderately reduce low density lipoprotein
(LDL) cholesterol, and elevate high density lipoprotein
(HDL) cholesterol [2]. Furthermore, fibrates may exert anti-
inflammatory effects and improve vascular function [3].
Therefore, targeting PPARa can be an effective way to
improve features belonging to the metabolic syndrome and
to reduce cardiovascular risk. As PPARs can be seen as lipid
sensors, dietary n-3 fatty acids deserve attention in this
respect. Especially the marine n-3 long chain poly-
unsaturated fatty acids (n-3 LCPUFA) eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) preferentially bind
to and activate PPARa [1]. However, these n-3 LCPUFA can
also activate PPARg and PPARd, two other PPAR isoforms
[1]. As fibrates, dietary n-3 LCPUFA have potent hypo-
triglyceridemic effects and can increase HDL cholesterol
[4]. Furthermore, the suggested beneficial effects on
inflammation and endothelial function may further
contribute to a reduction in cardiovascular risk. Stalenhoef
et al. have compared in hypertriglyceridemic subjects
gemfibrozil with n-3 LCPUFA and showed that both treat-
ments had favorable effects on serum lipid concentrations
and lipoprotein particle heterogeneity [5]. However, in that
study markers reflecting low-grade systemic inflammation
and endothelial function were not examined.
To establish the relevance of a dietary component as
a subtle, PPAR agonist with that of a strong, synthetic
PPARa agonist, we decided to compare side-by-side the
effects of n-3 LCPUFA with those of fenofibrate on inflam-
matory parameters, vascular function, and the serum
lipoprotein profile in overweight and obese subjects, who
are at increased risk to have or to develop the metabolic
syndrome.
Methods
Subjects
Caucasian subjects with a BMI of at least 27 kg/m2 were
recruited between the end of March and the end of August of
2007 via posters in the university and hospital buildings, and
via advertisements in local newspapers. Subjects came to
the university for a screening visit. On this visit, fasting blood
was sampled for analyses of serum lipids and lipoproteins.
In addition, height and body weight were determined.
Furthermore, subjects had to complete a medical and
general questionnaire. Exclusion criteria were BMI below
27 kg/m2, impairment of kidney (creatinine > 150 mmol/L)
and liver function (ALAT, ASAT, ALP, GGT or total
bilirubine > 2 times upper limit of normal), serum totalcholesterol above 8 mmol/L, serum triglycerides above
4 mmol/L, taking medication that could influence the study
outcome or could interfere with fenofibrate treatment, use
of fish oil supplements, consumption of plant sterol or stanol-
enriched food products, having donated blood within
1 month prior to the start of the study, having a diagnosis of
any long-term medical condition (e.g. diabetes, cardiovas-
cular diseases, epilepsy) or experiencing strong symptoms of
allergy. Subjects receivedoral andwritten informationabout
the nature and risk of the experimental procedures before
their written informed consent before the start of the study.
The study was approved by the Medical Ethical Committee of
Maastricht University.
After the screening of 34 subjects, 26 subjects met all
our inclusion criteria and started the study. After inclusion,
6 subjects dropped out (1 man underwent surgery for an
aneurysm, 1 woman had complained about vapors during
the placebo period, 1 man and 1 woman did not regularly
attend appointments and were excluded, 1 man had
a work-related reason, and 1 man had personal reasons).
Thus, ten men and ten women completed the trial. Baseline
characteristics are presented in Table 1.
Study design
The study had a randomized, double-blind, placebo-
controlled, crossover design. Each subject enrolled in
random order in a fish oil, a fenofibrate and a placebo
period for 6 weeks with a wash-out period of at least 2
weeks between the intervention periods. During the fish oil
intervention, subjects had to consume daily 8 fish oil
capsules (Marinol C-38, Lipid Nutrition, Wormerveer, the
Netherlands), providing approximately 3.7 g/d n-3 LCPUFA
(1.7 g/d EPA and 1.2 g/d DHA,) and 2 capsules placebo-
matching fenofibrate (200 mg/d cellulose). During the
fenofibrate period, subjects consumed 2 capsules providing
200 mg/d micronized fenofibrate (Lipanthyl, Fournier
Laboratories, Dijon, France) and 8 placebo-matching fish oil
capsules (containing 80% High Oleic Sunflower Oil (HOSO)).
During the placebo period, subjects received 8 HOSO
capsules and 2 cellulose capsules. Subjects had to ingest
half of the capsules before breakfast and the other half
before dinner with a glass of water. Subjects were
restricted in their fish consumption to a maximum of one
portion a week. During the study, subjects recorded any
symptom of illness, visits to physician, medication used,
alcohol consumption, and any deviations from the protocol
in diaries. Body weight was recorded at weeks 0, 5 and 6 of
each intervention period and blood pressure was monitored
using a sphygmomanometer (Omron M7, CEMEX Medische
Techniek BV, Nieuwegein, the Netherlands). At the end of
each intervention period, energy and nutrient intakes
of the previous 4 weeks were estimated using a food
frequency questionnaire (FFQ) [6].
Table 1 Baseline characteristics of the participants.a
All (n Z 20) Females (n Z 10) Males (n Z 10)
Age (years) 52  12 51  14 54  10
BMI (kg/m2) 33  5 34  5 31  5
Waist circumference (cm) 117  12 116  11 118  13
Systolic blood pressure (mmHg) 131  14 122  9 141  10
Diastolic blood pressure (mmHg) 91  8 85  7 96  5
Total cholesterol (mmol/L) 6.23  1.18 5.89  1.45 6.59  0.78
LDL cholesterol (mmol/L) 3.97  1.09 3.54  1.23 4.41  0.75
HDL cholesterol (mmol/L) 1.52  0.44 1.67  0.46 1.38  0.39
Triglycerides (mmol/L) 1.63  0.59 1.51  0.52 1.76  0.65
Glucose (mmol/L) 5.34  0.73 5.22  0.54 5.45  0.88
Criteria metabolic syndrome (n)b 2.2  1.0 1.6  0.7 2.7  1.1
Diagnosis metabolic syndrome (n)b 7 1 6
a Values are expressed as mean  SD.
b According to the National Cholesterol Education Program Adult Treatment Panel III guidelines.
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Blood sampling
In weeks 5 and 6 of each intervention period, subjects
arrived in the morning after an overnight fast and after
abstinence from drinking alcohol the preceding day. Venous
blood was sampled in BD vacutainer tubes (Becton Dick-
inson Company, NJ, USA). Serum was obtained by clotting
the blood for 30 min, followed by 30 min centrifugation at
2000g. EDTA, NaF and heparin plasma were obtained by
centrifugation at 2000g for 30 min at 4 C, directly after
sampling. Serum and plasma aliquots were snap frozen and
stored at 80 C until analysis.
Clinical safety parameters
Serumconcentrations ofmarkers of liver and kidney function
(total bilirubin, aspartate aminotransferase (ASAT), alanine-
aminotransferase (ALAT), alkaline phosphatase (ALP), g-
glutamyl transpeptidase (g-GT), ureum, and creatinine)
fromweek 6 of each intervention period were determined at
the department of Clinical Chemistry, University Hospital
Maastricht (Beckman Synchron CX7 Clinical systems,
Beckman).
Plasma lipids, lipoproteins and glucose
Plasma EDTA samples from weeks 5 and 6 were analyzed
separately for concentrations of serumtotal cholesterol (ABX
Diagnostics, Montpelier, France), HDL cholesterol (precipi-
tation method; Roche Diagnostics Corporation, Indianapolis,
IN), and triglycerides corrected for free glycerol (Sigmae
Aldrich Chemie, Steinheim, Germany). Serum LDL choles-
terol concentrations were calculated with the formula of
Friedewald et al. [7]. After analysis, values of weeks 5 and 6
were averaged. The free EPA and DHA content in plasma as
a compliance marker, was determined with LC-MS method-
ology (TNO, Zeist, the Netherlands) as described [8] in
heparin plasma of week 6 from each period. The plasma
lipoprofile (number and size op lipoprotein particles) was
analyzed by NMR (NMR LipoProfile test, Liposcience Inc.,
Raleigh, NC, USA) in a pooled sample from weeks 5 and 6 of
each treatment period. NaF plasma samples from weeks 5
and 6 were analyzed for free fatty acids (FFA) with the WakoNefa C test kit (Wako Chemicals, Neuss, Germany) and
plasmaglucosewith thehexokinasemethod (LaRoche, Basel,
Switzerland), and values were averaged.
Markers of inflammation and vascular activity
Plasma EDTA samples from weeks 5 and 6 of each inter-
vention period were pooled prior to the analysis of plasma
markers of inflammation and vascular activity. High sensi-
tive CRP (hsCRP) was measured with a immunoturbidi-
metric assay using commercially available kit (Kamiya
Biomedical Company, Seattle, WA, USA). The MS2400
Human Vascular Injury II Assay (Meso Scale Discovery, MD,
USA) was used for analysis of soluble Vascular Cell Adhesion
Molecule-1 (sVCAM1) and soluble Intracellular Adhesion
Molecule-1 (sICAM1). Tumor Necrosis Factor a Receptors
(TNFR) 1 and 2 were measured with the MS2400 TNFR1 and
TNFR2 ultrasensitive assay (Meso Scale Discovery, MD, USA).
Plasma concentrations of Macrophage Chemoattractant
Protein 1 (MCP1) were measured with the MA2400 Human
MCP1 ultrasensitive assay (Meso Scale Discovery, MD, USA).
Soluble endothelial selectin (sE-selectin) concentrations
were measured by enzyme-linked immunosorbent assay
(ELISA) as described [9]. Plasma Tumor Necrosis Factor
a (TNFa) and interleukin 6 (IL6) were measured with an
ELISA kit from R&D systems (Abingdon, UK). All samples
from one subject were analyzed in the same analytical run
in duplicate. The intra- and inter-assay variation coeffi-
cients were below 10% for all measured parameters.
Statistics
The power to detect a true difference of 0.20 mmol/L in
triglyceride concentrations between treatments after
adjustment for multiple comparisons was 80%. Normality
was checked visually and tested with the ShapiroeWilk
test. Glucose and sE-selectin concentrations were log
transformed to achieve normality. Differences in fasting
levels at the end of the intervention periods were
compared with a General Linear Model for Univariate
ANOVA with treatment as fixed factor and subject number
as random factor. Since there were no significant interac-
tions between treatment and gender, and treatment and
Table 2 Effects of fish oil and fenofibrate on serum lipid concentrations and plasma glucose concentrations.a
Placebo Fenofibrate Fish oil
Total cholesterol (mmol/L) 6.01  1.32 5.42  1.20c 6.29  1.42d
LDL cholesterol (mmol/L 3.74  1.14 3.30  1.09c 4.08  1.24c, d
HDL cholesterol (mmol/L) 1.44  0.41 1.58  0.42c 1.54  0.48
FFA (mM/L) 396  236 368  237 357  209
Glucose (mmol/L)b 5.3  0.7 5.4  0.7 5.6  0.7
a Values are expressed as mean  SD.
b Log transformed concentrations were used for statistical analysis.
c P<0.05 versus placebo period.
d P<0.05 versus fenofibrate period.
Figure 1 The effects of fish oil and fenofibrate treatment on
serum triglyceride concentrations. Data are presented as
mean  SD. An asterisk indicates a significant effect compared
to placebo (P < 0.05).
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were not included in the final model. To adjust for multiple
comparisons, a Tukey Honestly Significantly Difference
(HSD) procedure was carried out. A P < 0.05 was considered
to be statistically significant. Data are presented as
mean  SD. Statistical analysis was performed using SPSS
15.0 for Windows.
Results
Compliance, dietary intake, body weight and blood
pressure
The calculated main daily capsule intake was 93% during
the fish oil period, 95% during the fenofibrate period and
95% during the placebo period, indicating a good compli-
ance. This was confirmed for the fish oil period, as plasma
free EPA and DHA concentrations increased by 358%
(P < 0.001) and 105% (P < 0.001) compared to the placebo
period, and by 463% (P < 0.001) and 157% (P < 0.001)
compared to the fenofibrate period, respectively. Total
energy intake and the proportions of energy from fat,
carbohydrates and protein, and the amounts of fiber,
alcohol and cholesterol in the diet did not differ between
the treatment groups (data not shown). Furthermore, body
weight and blood pressure did not change between the
treatment periods (data not shown).
Effects on serum lipids and lipoprofile and plasma
glucose
Compared to placebo, fenofibrate reduced serum total
cholesterol and LDL cholesterol by respectively 9%
(0.59 mmol/L, P Z 0.001) and 11% (0.45 mmol/L,
PZ 0.004; Table 2). Fish oil tended to increase the concen-
tration of total cholesterol (PZ 0.099) and increased that of
LDL cholesterol by 10% (0.34 mmol/L, PZ 0.035) compared
to placebo. Both fenofibrate and fish oil effectively reduced
serum triglyceride concentrations by respectively 27%
(0.61 mmol/L, P < 0.001) and 13% (0.34 mmol/L,
PZ 0.048) compared with placebo (Fig. 1). HDL cholesterol
concentrations increased by 11% (0.13 mmol/L, PZ 0.013)
after fenofibrate treatment, whereas fish oil tended to
increase HDL cholesterol (PZ 0.076) compared to placebo.
Compared with fenofibrate treatment, HDL cholesterol
(PZ 0.737) and triglyceride concentrations (PZ 0.133)were
comparable after fish oil intake, but total cholesterol(0.91 mmol/L, P< 0.001) and LDL cholesterol (0.78 mmol/L,
P< 0.001) were increased. Concentrations of free fatty acids
were not affected by either treatment.
Fish oil tended to raise fasting plasma glucose concen-
trations compared to placebo (0.24 mmol/L, P Z 0.056)
and fenofibrate treatment had no effect (P Z 0.721)
compared to placebo. At the end of the intervention
period, glucose concentrations between fish oil and feno-
fibrate treatment (P Z 0.250) did not differ.
Compared to placebo, fenofibrate significantly reduced
total VLDL particle numbers (23 nmol/L, P Z 0.001), in
particular large (2.4 nmol/L, P Z 0.003) and medium
VLDL particles (14 nmol/L, P Z 0.001). Fish oil reduced
the number of large VLDL particles (3.0 nmol/L,
P < 0.001), although the total number of VLDL particles was
not affected. It increased however the total number of LDL
particles (224 nmol/L, P Z 0.005), but decreased the
number of IDL particles (28 nmol/L, PZ 0.016). For HDL,
fenofibrate decreased HDL size (0.11 nm, P Z 0.025) and
increased the number of medium HDL particles (3.1 mmol/
L, PZ 0.011). Fish oil had no overall effect on HDL size, but
increased the number large HDL particles (1.5 mmol/L). Fish
oil treatment resulted in higher particle numbers of total
VLDL (16 nmol/L, P Z 0.02), medium VLDL (13 nmol/L,
P Z 0.002), total LDL (334 nmol/L, P < 0.001), large LDL
(132 nmol/L, P Z 0.006) and small LDL (215 nmol/L,
P Z 0.043) compared to fenofibrate treatment (Table 3).
The number of large HDL particles and HDL size were larger
Table 3 Effects of fenofibrate and fish oil consumption on plasma NMR lipoprofile.a
Placebo Fenofibrate Fish oil
Particle numbers
Total VLDL 63  28 40  24b 56  40c
Large VLDL 4.9  3.7 2.4  2.6b 1.8  3.2b
Medium VLDL 26  17 12  9b 26  24c
Small VLDL 32  18 26  15 28  18
Total LDL 1484  554 1374  548 1708  679b, c
IDL 55  62 40  47 27  43b
Large LDL 523  252 439  176 571  292c
Small LDL 906  614 895  497 1110  727c
Medium small LDL 191  139 190  118 223  145
Very small LDL 714  496 705  382 887  586c
Total HDL 36  8 38  6 36  8
Large HDL 7.1  4.4 6.7  3.9 8.6  5.3b, c
Medium HDL 4.5  5.4 7.6  6.0b 2.8  3.4c
Small HDL 25  6 24  7 25  6
Particle sizes
VLDL 56  16 53  10 48  8b
LDL 21  1 21  1 21  1
HDL 8.9  0.5 8.7  0.4b 8.9  0.5c
a Values are means  SD (nZ 20). Particle numbers are expressed in nmol/L, except for HDL particles, which are expressed in mmol/L.
Particle sizes are expressed in nm.
b P<0.05 versus placebo period.
c P<0.05 versus fenofibrate period.
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tively). The number of medium HDL particles was smaller
after fish oil treatment compared to fenofibrate treatment
(4.8 nmol/L, P < 0.001).
Effects on plasma makers of inflammation and
vascular activity
Concentrations of TNFR1, TNFR2 hsCRP, TNFa, IL6, sICAM1
and sVCAM1 did not differ between the treatments (Table 4).
Compared with placebo, the chemokine MCP1, however,
increased upon fenofibrate treatment (28 ng/mL,Table 4 Effects of fenofibrate and fish oil treatment on marke
Placebo
Immune receptors
TNFR1 (ng/mL) 3.4  0.8
TNFR2 (ng/mL) 4.3  1.1
Acute phase protein
CRP (mg/L) 4.0  2.8
Cytokines
TNFa (pg/mL) 2.0  0.8
IL6 (pg/mL) 2.8  1.1
MCP1 (ng/mL) 257  69
Adhesion molecules
ICAM (ng/mL) 275  50
VCAM (ng/mL) 440  102
E-selectin (ng/mL)b 76  32
a Values are mean  SD.
b Log transformed concentrations were used for statistical analysis.
c P<0.05 versus placebo period.
d P<0.05 versus fenofibrate period.PZ 0.034), but remained unaffected after fish oil treatment
(P Z 0.204) (Table 4). Further, fenofibrate significantly
lowered sE-selectin concentrations compared to both
placebo (4.1 ng/mL, PZ 0.034) and fish oil (5.7 ng/mL,
P Z 0.014), whereas fish oil treatment had no effect
compared to placebo (PZ 0.932).
Side effects
Fish oil andmicronized fenofibratewerewell tolerated by all
subjects. Fish oil hadno significant effects onmarkers of liver
and kidney function (Table 5) compared to placebo. Inrs of inflammation and vascular function.a
Fenofibrate Fish oil
3.5  0.7 3.4  0.6
4.6  0.9 4.1  1.0
3.6  1.9 4.3  3.7
2.0  0.6 2.0  0.7
2.7  1.1 2.7  1.0
285  87c 267  64
304  105 267  48
451  95 425  86
72  32c 77  34d
Table 5 Effects of fenofibrate and fish oil treatment on markers of kidney and liver function.a
Placebo Fenofibrate Fish oil Reference valuesb
Total bilirubin (mmol/L) 14  7 12  3 14  5 0e17
ALAT (IU/L) 28  8 50  52c 38  27 5e45
ASAT (IU/L) 17  7 30  26c 22  10 5e35
ALP (IU/L) 75  24 67  23c 73  21 30e140
g-GT (IU/L) 34  10 58  61 35  10 2e50
Ureum (mmo/L) 5.0  0.9 5.4  1.3 4.8  0.9 3e7
Creatinine (mmol/L) 78  12 88  16c 78  13d 53e110
a Values are mean  SD.
b Reference values from the department of Clinical Chemistry, University Hospital Maastricht, Maastricht, the Netherlands.
c P<0.05 versus placebo period.
d P<0.05 versus fenofibrate period.
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PZ 0.043). For 5 out of the 20 subjects valueswereabove the
normal range (Laboratory of Clinical Chemistry, University
Hospital Maastricht, Maastricht, the Netherlands). Fenofi-
brate also increased ASAT (13 IU/L, P Z 0.016L) and
decreased ALP concentrations compared to placebo (8 IU/
L, PZ 0.019). Creatinine concentrations were higher after
fenofibrate treatment compared to placebo (9.8 mmol/L,
P < 0.001) and fish oil treatment (9.4 mmol/L, P < 0.001).
Although g-GT did not change significantly (P Z 0.979), it
slightly exceeded the normal range upon fenofibrate treat-
ment compared to placebo for 4 out of 20 subjects.
Discussion
Overweight and obese subjects are often characterized by
a disturbed lipid and lipoprotein profile, low-grade systemic
inflammation, andendothelial dysfunction. Away to improve
these metabolic aberrations is by targeting PPARa. We
hypothesized that a dietary intervention with n-3 LCPUFAs,
as non-selective PPARa agonists, could be an alternative for
a strongmedicinal agonist. Therefore, we directly compared
the effects of these n-3 LCPUFAs with those of fenofibrate on
a broad range of biomarkers for cardiovascular disease.
However, we found that fenofibrate (200 mg/d) and n-3
LCPUFA (3.7 g/d) treatment for 6 weeks did not improve
markers for low-grade systemic inflammation and that
fenofibrate had more profound effects on plasma lipids and
vascular activity compared to fish oil in overweight and obese
individuals.
Studies on fenofibrate have shown inconsistent results
regarding effects on low-grade inflammation and vascular
activity [10e12]. We found that fenofibrate reduced
sE-selectin concentration compared to placebo and fish oil
treatment in overweight and obese subjects. This finding
corresponds to that of Hogue et al., who found in type 2
diabetic patients, that micronized fenofibrate (200 mg/d)
for 6 weeks reduced plasma sE-selectin, but did not affect
concentrations of hsCRP, sICAM1 and sVCAM1 [11]. In
contrast, Ryan et al. showed in an obese population, that
fenofibrate reduced sVCAM1, sICAM1, TNFa, IL6, IL1b, but
did not affect sE-selectin concentrations [12]. The reduced
sE-selectin concentration as we observed suggests benefi-
cial effects of fenofibrate on vascular activity, since
E-selectin is involved in the adherence of leukocytes in the
process of atherosclerosis [13]. However, this seems tocontradict the observed increase in MCP1 concentrations
after fenofibrate treatment compared to placebo, since
this chemokine is responsible for attracting monocytes to
the injured endothelium [13]. For fish oil, human inter-
vention studies using doses ranging between 1.1 and 6.6 g/d
n-3 LCPUFAs are inconsistent and do not often report
beneficial effects on inflammatory markers and cellular
adhesion molecules [14e18]. In that respect, our results
agree with those of other studies in obese men [17,18] and
healthy middle-aged individuals [19], although our sample
size may have been too limited to detect statistically
significant changes in IL6 and TNFa.
The main well-established effects of fenofibrate and fish
oil on plasma lipids are their hypotriglyceridemic effects
[4,20]. Indeed, we also found that both treatments similarly
lowered serum triglyceride concentrations and the number
of large triglycerideerich VLDL particles. These effects have
been ascribed to an increased hepatic lipolysis and
decreased lipogenesis [21,22], pathways which are under
control of PPARa [2]. We demonstrated a small increase in
HDL cholesterol concentrations after fenofibrate and fish oil
treatment, reflected by increases in medium size and large
size HDL particles. The increased delivery of surface
remnants from the catabolism of VLDL particles, together
with a PPARa-induced expression of apoA1 and apoA2, the
main apolipoproteins of HDL, may contribute to the raise in
HDL cholesterol [23]. Furthermore, PPARa may stimulate
reverse cholesterol transport via induction of ATP Binding
Cassette protein A1 (ABCA1) [24]. Regarding the effects of
fish oil and fenofibrate on triglycerides and HDL cholesterol,
it is important to note that thedegree of these effects largely
depend on baseline plasma lipid levels [4,25,26]. In contrast
to fenofibrate, fish oil increased LDL cholesterol concentra-
tions. Others have also reported that high dose supplemen-
tation of EPA and DHA can raise LDL cholesterol by 5e10%
[26]. In this respect, some groups of subjects may be more
sensitive than other groups and it has been suggested that
this variability in LDL cholesterol response is related to the
apoE4 variant of apolipoprotein E [27]. For fenofibrate and
fish oil treatments, it has been reported that the LDL particle
size changes into a more buoyant type, which may be less
atherogenic [5]. In our study, however, this could not be
confirmed. Fish oil increased large, small and very small LDL
compared to fenofibrate. These findings seem inconsistent in
relation to our observed reduction in triglycerides and
increase in large HDL particles. When plasma triglycerides
972 M.C.E. Bragt, R.P. Mensinkare reduced, the proportion or concentration of small LDL
particles is expected to be reduced and that of large HDL
increased [28]. We do not have an explanation for these
unexpected results.
Finally, we observed a non-significant increase of fasting
plasma glucose after fish oil treatment. This agrees with
a meta-analysis by Balk et al. [26], who reported a very
small and non-significant average net increase in fasting
plasma glucose after treatment with n-3 LCPUFAs.
In summary, although n-3 LCPUFAs and fenofibrate can
both activate PPARa, this study in overweight and obese
subjects showed that both fenofibrate (200 mg/d) and fish
oil (7.2 g/d, providing 1.7 g/d EPA and 1.2 g/d DHA)
treatment for 6 weeks have different effects on cardio-
vascular risk markers. Both interventions equally lowered
serum triglycerides and raised HDL cholesterol, which
agrees with few other human studies that have compared
side-by-side the effects of fibrates with those of n-3
LCPUFAs [5,29,30] Also, as in several other studies [26], fish
oil treatment increased LDL cholesterol. Both treatments,
however, did not improve markers for low-grade systemic
inflammation, while fenofibrate had more profound, but
apparently conflicting, effects on markers for vascular
activity compared to fish oil. Still, like fenofibrate [30],
LCPUFAs may lower cardiovascular risk through beneficial
effects on other cardiovascular risk factors such as blood
pressure, arrhythmias and platelet function [31,32].
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